Live starting prices

#novo-nordisk

2 articles tagged #novo-nordisk.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#alcohol 1#alternatives 1#ban 1#before-and-after 1#beginners 2#berberine 1#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#clinical-research 1#clinical-trials 1#comparison 2#compounded 8#compounded-glp1 1#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 2#fda 4#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#natures-ozempic 1#news 2#novo-nordisk 2#online-prescription 1#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 9#pcos 1#personalized-treatment 1#pill 1#pipeline 1#policy 1#precision-medicine 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 2#safety 5#savings-card 1#schedule 1#semaglutide 24#serena-williams 1#shortage 1#side-effects 10#storage 1#supplements 2#surmount 2#surmount-5 1#telehealth 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 22#travel 1#tsa 1#type-2-diabetes 1#wada 1#warning-letters 1#wegovy 17#wegovy-hd 1#wegovy-pill 3#weight-loss 26#weight-loss-plateau 1#without-insurance 1#zepbound 18
Editorial still-life illustrating Foundayo and Wegovy pill comparison for weight loss
AnalysisComparisonsJuly 16, 2026• 20 min read

Foundayo vs Wegovy Pill (2026): Weight Loss, Dosing & From-$149 Prices

Updated August 14, 2026: Oral Wegovy produced 16.6% weight loss in OASIS vs Foundayo's 12.4% in ATTAIN-1; these were separate trials. Both manufacturer-direct cash-pay floors now start at $149/mo. Foundayo follows a $149-$349 dose/refill ladder and requires no fasting; NovoCare's Wegovy pill price is dose-dependent and requires a 30-minute pre-dose fast.

Editorial still-life illustrating CagriSema, an investigational injectable weight loss drug from Novo Nordisk
AnalysisNews & PipelineJune 16, 2026• 9 min read

CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Embody

7.3/10
from $69/mo·Compounded
Visit EmbodyReview

Gala

7.2/10
from $149/mo·Brand & Compounded
Visit GalaReview

Ro

7.2/10
$149/mo membership + medication·Brand
Visit RoReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.